Pfizer registers Phase 3 study of RSVpreF revaccination in OLDER ADULTS
Pfizer has registered a Phase 3, randomized, OPEN-LABEL study to EVALUATE the safety and tolerability of a second dose of RSVpreF given approximately 5 years after the initial dose. The study plans to enroll 750 participants, start on October 29, 2026, and reach primary completion on February 7, 2029.
Primary source
ClinicalTrials.gov registry record, October 21, 2026
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults
Read the source: A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation